Assessment of α1-antitrypsin and α2- macroglobulin levels in obese patients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 12, 2008, Pages 713-718

  Świa̧tkowska Stodulska, Renata ^a,b   Babińska, Anna ^a   Skibowska Bielińska, Anna ^a   Sworczak, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Klinika Endokrynologii i Chorób Wewn tonych   (Poland)

Author keywords

Metabolic syndrome; Obesity

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CLOTTING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; OBESITY; PROTEIN BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; POLAND; RISK FACTOR;

ADULT; ALPHA 1-ANTITRYPSIN; ALPHA-MACROGLOBULINS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POLAND; RISK FACTORS;

EID: 58449132251     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.536     Document Type: Article

References (37)

1. Świa̧tkowska-Stodulska R, Kazimierska E, Sworczak K, Czȩstochowska E. [Hemostatic disturbances in obesity]. Wiad Lek. 2007; 60: 185-188. Polish.
2. Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab. 2002; 87: 660-665.
3. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly. 2002; 132: 241-252.
4. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003; 108: 420-425.
5. 1 and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 2000; 49: 1374-1380.
6. Avellone G, Di Garbo V, Cordova R, et al. Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution. Thromb Res. 1994; 75: 223-231.
7. Balleisen L, Bailey J, Epping PH, et al. Epidemiological study on factor VII, factor VIII, and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost. 1985; 54: 475-479.
8. Bastard JP, Pieroni L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother. 1999; 53: 455-461.
9. Cigolini M, Targher G, Bergamo IA, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vase Biol. 1996; 16: 368-374.
10. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993; 70: 380-385.
11. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest. 2002; 25: 899-904.
12. Folsom AR, Qamhieh HT, Wing RR, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 1993;13: 162-169.
13. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc. 2001; 60: 341-347.
14. Rasito GA, D'Agostino RB, Massaro J, et al. Association between obesity and a prothrombotic state: The Framingham Offspring Study. Thromb Haemost. 2004; 91: 683-689.
15. Bowles LK, Cooper JA, Howarth DJ, et al. Associations of haemostatic variables with body mass index: a community-based study. Blood Coagul Fibrinolysis. 2003; 14: 569-573.
16. Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. Histopathology. 2007; 50: 535-546.
17. Lubas W, Gutkowski K. C-reactive protein in cardiovascular diseases. Przegl Lek. 2006; 63: 562-566.
18. Mitosz D, Czupryniak L, Saryusz-Wolska M, et al. Adiponectinemia, inflammatory process activity, and endothelial dysfunction in patients with type 2 diabetes and acute coronary syndrome with ST elevation in relation to the severity of lesions in the coronary arteries. Pol Arch Med Wewn. 2007; 117: 343-349.
19. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000; 85: 3338-3342.
20. Dandona P, Weinstock R, Thusu K, et al. Tumor necrosis factor-α in sera of obese patients: fall with weight loss. J Clin Endocrionol Metab. 1998; 83: 2907-2910.
21. Brower MS, Harpel PC. α-1-antitrypsin-human leukocyte elastase complexes in blood: quantification by an enzyme-linked differential antibody immunosorbent assay and comparison with α-Z-plasmin inhibitor-plasmin complexes. Blood. 1983; 61: 842-849.
22. 1-antitrypsin. J Biol Chem. 1988; 263: 11613-11616.
23. 2 -macroglobulin revisited: results of a case-control study in children with symptomatic thromboembolism. J Thromb Haemost. 2007; 5: 1179-1184.
24. Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MH0)? Diabetes Metab. 2004; 30: 569-572.
25. Engström G, Stavenow L, Hedblad B, et al. Inflammation-sensitive plasma proteins and incidence of myocardial infarction in men with low cardiovascular risk. Arterioscler Thromb Vase Biol. 2003; 23: 2247-225).
26. Engström G, Hedblad B, Stavenow L, et al. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes. 2003; 52: 2097-2101.
27. Engström G, Stavenow L, Hedblad B, et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes. 2003; 52: 442-447.
28. Engström G, Hedblad B, Stavenow L, et al. Fatality of future coronary events is related to inflammation-sensitive plasma proteins: a population-based prospective cohort study. Circulation. 2004; 110: 27-31.
29. Engström G, Hedblad B, Stavenow L, et al. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arteriosder Thromb Vase Biol. 2004; 24: 1498-1502.
30. Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005; 90: 4145-4450.
31. Faraj M, Messier L, Bastard JP, et al. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia. 2006; 49: 1637-1646.
32. Cymerys M, Chyrek R, Bogdański P, et al. [Evaluation of acute-phase protein levels in obese patients with hypertension]. Pol Merk Lek. 2003; 88: 352-355. Polish.
33. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51: 1131-1137.
34. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X Diabetologia. 1997; 40: 1286-1292.
35. 1 AT) complex as a marker for in vitro diagnosis of prethrombotic states. Thromb Res. 1992; 66: 499-508.
36. Bogdański P, Chyrek R, Pupek-Musialik O, Jabtecka A. [Evaluation of selected acute phase proteins in patients with metabolic syndrome]. Pol Merk Lek. 2006; 21: 12-14. Polish.
37. Rugsarash W, Tungtrongchitr R, Petmitr S, et al. The genetic association between alpha-2-macroglobulin (A2M) gene deletion polymorphism and low serum A2M concentration in overweight/obese Thais Nutr Neuro- sci. 2006; 9: 93-98.